id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_6ynq6qchjve7xo2qwqmb3oy5yy	Carlos R. Becerra	A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92	2013	5	.pdf	application/pdf	4038	376	54	efficacy of this regimen followed by surgery in patients with resectable esophageal cancer. in the tumor of patients with resected esophageal adenocarcinomas after trimodality therapy predicts a poor outcome.5 Herein, we present the results of a single-arm, openlabel, phase II study with cetuximab and external beam radiation therapy for patients with newly diagnosed, potentially surgical consult; patient being agreeable to surgical resection of the primary tumor; no prior use of radiation or chemotherapy for cancer of the esophagus or GE junction; no In this phase II study, the addition of cetuximab to external beam radiation therapy in patients with potentially resectable esophageal cancers resulted in a pCR rate of 36.6% by A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92 A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92	./cache/work_6ynq6qchjve7xo2qwqmb3oy5yy.pdf	./txt/work_6ynq6qchjve7xo2qwqmb3oy5yy.txt